The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2023 | The need to improve treatment options for patients with lenalidomide-refractory multiple myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the importance of identifying alternative therapies for patients with lenalidomide-refractory multiple myeloma. Prof. Einsele notes that a majority of patients receiving lenalidomide relapse during or shortly after therapy, highlighting the need for earlier treatment with novel agents such as bispecific antibodies (BsAbs) and CAR T-cells. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
